Jyrki Mattila, MD, PhD

Jyrki Mattila is the Chairman of the Board of Aranda Pharma Ltd. Jyrki has over 30 years of experience in managerial positions in the pharmaceutical industry of which the past 16 years he has spent in the US. Currently he holds a position of Executive Vice President, Business Development at Recro Pharma. In the past he has served as Chief Business Officer at Lipocine and at iCeutica Inc. and as President and Chief Executive Officer at LZ Therapeutics, Inc. At Auxilium Pharmaceuticals Inc, Jyrki served as Executive Vice President, Business Development, Product Development and Technical Operations and contributed to Auxilium’s growth from a private start-up to a publicly-traded specialty pharmaceutical company. Prior moving to US, Jyrki held positions of increasing responsibility at Orion Corporation in business development, R&D and executive general management. Jyrki served as a Post-Doctoral Research Fellow at the University of Kansas Medical Center and holds a M.B.A. from the Helsinki School of Economics, a Ph.D. from the Department of Pharmacology at the University of Helsinki and a M.D. from the University of Helsinki Medical School.

Aki Prihti, MSc (Econ, BA)

Aki Prihti is a Non-Executive Director and Board member of Aranda Pharma Ltd. Aki has close to 20 years of experience in setting up, developing, and funding life science growth companies. Currently Aki serves as CEO of Aplagon Oy, a Finnish drug development company focused on vascular intervention related complications, and as CFO and Board member of Medtentia International Ltd Oy, a Finnish medical device company focused on catheter based mitral valve repair. Aki is also one of the founders of Inveni Capital, a life sciences focused venture capital fund, and a board member of Herantis Pharma Oyj. Aki received his MSc in Economy and Business Administration from Helsinki School of Economics and Business Administration, Finland.

Milla Koistinaho, PhD, Adjunct professor in Neurobiology

Milla Koistinaho is a founder, Non-Executive Director and Board member of Aranda Pharma Ltd. Milla has over 15 years of experience in commercializing biomedical inventions and developing business models especially in the therapeutic areas of CNS diseases and oncology. She has been a member of founding team in three start-up companies in Finland. For 9 years Milla has served as a founding CEO at Medeia Therapeutics Ltd and been responsible for IPR generation, leading research programs and partnerships, executing financing rounds and leading business development actions. Milla has also been CSO and CEO in Cerebricon Ltd serving clients in pharmaceutical development. She is well networked internationally and she has also worked as a postdoctoral researcher in biopharmaceutical projects at Eli Lilly and Company in the USA. Milla holds Adjunct Professorship in neurobiology at University of Eastern Finland. She has a PhD degree from the same university. Milla gained her PhD thesis in collaboration with Stanford University and Scios Inc., California, USA. Currently Milla is the Director of Life Sciences at the Helsinki Innovation Services Ltd, Finland.